Frequency of monitoring, non-adherence, and other topics dear to an anticoagulation clinic provider

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 3, 2013, Pages 320-324

  Clark, Nathan P ^a,b  

^a Clinical Pharmacy Anticoagulation and Anemia Service   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adherence; INR; Monitoring; Subtherapeutic; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DRUG INDICATION; EMBOLISM; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS;

AGE FACTORS; ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; THROMBOEMBOLISM; WARFARIN;

EID: 84876666736     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0887-y     Document Type: Conference Paper

References (16)

1. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH, American College of Chest Physicians (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2Suppl):e152S-e184S
2. Fitzmaurice DA (2008) Oral anticoagulation should be managed in the community with treatment aimed at standard therapeutic targets and increased recall intervals. J Thromb Haemost 6(10):1645-1646
3. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M (2011) Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 155(10):653-659
4. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM, Warped Consortium (2010) Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 8(4):744-749
5. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM, Warfarin Associated Research Projects and other EnDeavors (WARPED) Consortium (2009) Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 114(5):952-956
6. Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Kimmel SE (2007) Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 22(9):1254-1259 (Pubitemid 47247293)
7. Orensky IA, Holdford DA (2005) Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy 25(12):1801-1808 (Pubitemid 41790102)
8. Davis NJ, Billett HH, Cohen HW, Arnsten JH (2005) Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 39(4):632-636 (Pubitemid 40396615)
9. Kimmel SE, Troxel AB, Loewenstein G, Brensinger CM, Jaskowiak J, Doshi JA, Laskin M, Volpp K (2012) Randomized trial of lottery-based incentives to improve warfarin adherence. Am Heart J 164(2):268-274
10. Witt D, Delate T, Clark N, Garcia D, Hylek E (2012) Nonadherence with INR monitoring and anticoagulant complications. Poster presented at The American Society of Health Systems Pharmacy Summer Meeting, Baltimore 9-13 June 2012
11. Rose AJ, Ozonoff A, Berlowitz DR, Ash AS, Reisman JI, Hylek EM (2011) Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest 140(2):359-365
12. Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L (2010) Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thromb Res 125(5):393-397
13. Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF (2003) Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 123(2):499-503 (Pubitemid 36269436)
14. Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA, Warfarin-Associated Research Projects and Other Endeavors Consortium (2008) Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Pharmacotherapy 28(8):960-967
15. Dentali F, Riva N, Malato A, Saccullo G, Siragusa S, Ageno W (2009) Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. J Thorac Cardiovasc Surg 137(1):91-93
16. Dentali F, Pignatelli P, Malato A, Poli D, Di Minno MN, Di Gennaro L, Rancan E, Pastori D, Grifoni E, Squizzato A, Siragusa S, Di Minno G, Ageno W (2012) Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. Am J Hematol 87(4):384-387